TENUATE DOSPAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TENUATE DOSPAN (TENUATE DOSPAN).
Releases norepinephrine from nerve terminals in the lateral hypothalamic feeding center, reducing appetite.
| Metabolism | Hepatic via CYP3A4 and other CYP enzymes |
| Excretion | Renal excretion of unchanged drug and metabolites; approximately 85-90% of the dose is excreted in urine within 48 hours, with less than 5% in feces. |
| Half-life | The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function, though clinical effects may last longer due to tissue distribution. |
| Protein binding | Approximately 20-30% bound to plasma proteins. |
| Volume of Distribution | Approximately 5-10 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Rapidly absorbed from the gastrointestinal tract; absolute oral bioavailability is about 10-20% due to extensive first-pass hepatic metabolism. |
| Onset of Action | Oral administration: 30-60 minutes. |
| Duration of Action | Oral immediate-release: 4-6 hours; extended-release formulation (Tenuate Dospan) provides therapeutic effects for 8-12 hours due to sustained release. |
25 mg orally three times a day, 1 hour before meals, or 75 mg extended-release orally once daily in the morning.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-59 mL/min), use with caution and consider dose reduction. |
| Liver impairment | Contraindicated in severe hepatic impairment. For Child-Pugh A or B, use with caution and consider reducing dose to 12.5 mg twice daily. |
| Pediatric use | Not recommended for use in children under 12 years. For adolescents 12-17 years, same adult dosing may be used under strict supervision. |
| Geriatric use | Initiate at lower dose (12.5 mg twice daily) due to increased sensitivity and risk of adverse effects. Maximum dose 75 mg per day. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TENUATE DOSPAN (TENUATE DOSPAN).
| Breastfeeding | Excretion in human milk unknown; risk of serious adverse reactions in nursing infants (e.g., CNS stimulation, growth suppression). Use during breastfeeding contraindicated. M/P ratio not established. |
| Teratogenic Risk | FDA Pregnancy Category X: Teratogenic effects demonstrated in animal studies; contraindicated in pregnant women due to increased risk of fetal malformations, particularly in the first trimester. Potential for neonatal withdrawal symptoms (hyperexcitability, feeding disorders) with third trimester exposure. |
■ FDA Black Box Warning
None
| Serious Effects |
["Advanced arteriosclerosis","Cardiovascular disease","Moderate to severe hypertension","Hyperthyroidism","Glaucoma","Agitated states","History of drug abuse","During or within 14 days of MAOI therapy"]
| Precautions | ["Pulmonary hypertension","Valvular heart disease","Seizures","Psychiatric disturbances","Tolerance and dependence","May impair ability to drive or operate machinery"] |
Loading safety data…
| Fetal Monitoring |
| Maternal: Blood pressure, heart rate, central nervous system stimulation signs, weight loss, electrolyte imbalances. Fetal: Fetal growth and wellbeing monitoring if inadvertent use discovered; assess for neonatal withdrawal post-delivery. |
| Fertility Effects | May impair female fertility: anovulation, menstrual irregularities due to altered reproductive hormone profiles at therapeutic doses. Reversible upon discontinuation. Nursing mothers: potential for milk suppression. |